CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PROPANTHERA aims to revolutionize the treatment of pancreatic and prostate cancers by developing a minimally invasive technique using targeted radiofrequency ablation. This method seeks to eliminate tumors while preserving organ function, reducing recovery time and complications compared to traditional surgical approac…
Pancreatic cancer (PaC) is a leading cause of cancer-related death in the Western world and its incidence is increasing.
Prostate cancer (PrC) is the 2nd most frequent cancer in men and the 5th leading cause of death globally.
These tumors arise in exocrine glands with secretory ducts.
Standard treatments like the Whipple procedure or radical prostatectomy are aggressive and carry significant morbidity. PROPANTHERA proposes a first-in-class, minimally invasive alternative: targeted radiofrequenc…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Barcelona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, MONTCADA I REIXAC
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, Valencia
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
